Hall FL - Search Results

1

Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype.

Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T. Guibinga GH, et al. Among authors: hall fl. Mol Ther. 2004 Jan;9(1):76-84. doi: 10.1016/j.ymthe.2003.09.018. Mol Ther. 2004. PMID: 14741780 Free article.

2

Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze.

Behrens A, Gordon EM, Li L, Liu PX, Chen Z, Peng H, La Bree L, Anderson WF, Hall FL, McDonnell PJ. Behrens A, et al. Among authors: hall fl. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):968-77. Invest Ophthalmol Vis Sci. 2002. PMID: 11923236

3

Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver.

Lenz HJ, Anderson WF, Hall FL, Gordon EM. Lenz HJ, et al. Among authors: hall fl. Hum Gene Ther. 2002 Aug 10;13(12):1515-37. doi: 10.1089/10430340260185148. Hum Gene Ther. 2002. PMID: 12215272 No abstract available.

4

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Song JC, McDonnell PJ, Gordon EM, Hall FL, Anderson WF. Song JC, et al. Among authors: hall fl. Hum Gene Ther. 2003 Feb 10;14(3):306-9. Hum Gene Ther. 2003. PMID: 12675032 Clinical Trial. No abstract available.

5

First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.

Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL. Gordon EM, et al. Among authors: hall fl. Int J Oncol. 2004 Jan;24(1):177-85. Int J Oncol. 2004. PMID: 14654955 Clinical Trial.

6

Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors.

Dong D, Dubeau L, Bading J, Nguyen K, Luna M, Yu H, Gazit-Bornstein G, Gordon EM, Gomer C, Hall FL, Gambhir SS, Lee AS. Dong D, et al. Among authors: hall fl. Hum Gene Ther. 2004 Jun;15(6):553-61. doi: 10.1089/104303404323142006. Hum Gene Ther. 2004. PMID: 15212714

7

Nanotechnology blooms, at last (Review).

Gordon EM, Hall FL. Gordon EM, et al. Among authors: hall fl. Oncol Rep. 2005 Jun;13(6):1003-7. Oncol Rep. 2005. PMID: 15870914 Review.

8

Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.

Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Bruckner HW, Hall FL. Gordon EM, et al. Among authors: hall fl. Int J Oncol. 2006 Nov;29(5):1053-64. Int J Oncol. 2006. PMID: 17016635

9

Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.

Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL. Gordon EM, et al. Among authors: hall fl. Int J Oncol. 2007 Jun;30(6):1297-307. Int J Oncol. 2007. PMID: 17487349 Clinical Trial.

10

Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB, Hall FL. Gordon EM, et al. Among authors: hall fl. Int J Oncol. 2008 Oct;33(4):665-75. Int J Oncol. 2008. PMID: 18813779

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters